PARKHOSPS · NSE
Park Medi World Limited
₹282.05
+1.49% (+₹4.15)
Prev. close
₹277.9
Volume
10,71,510
Delivery %
48.6%
As of
18 Sept 2026
Price history
Emkay Global Financial Services Analysis · Emkay Global Financial Services · 06 Aug 2026
“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.”
Published mid-session at 14:38 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x …” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Park Medi World | PENDING | ||||
“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.” Rating & targetTrack opinion → This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Park Medi World, setting a long-term target of ₹350. This outlook is driven by management's plan to expand ca…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Park Medi World | PENDING |
Fundamentals
About Park Medi World Limited
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Sanjay Sharma
Headquarters
Gurugram
Employees
6,423
Website
parkhospital.inExchange
View on NSE ↗Key stats
Market cap
₹11,953.69 Cr
P/E ratio (TTM)
42.3
EPS (TTM)
₹6.55
Beta (1Y · daily vs NIFTY 50)
0.84
Shares float
6.71 Cr
EPS · quarter ended Jun 2026
₹2.05
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,252.38 Cr | ₹1,229.06 Cr | ₹1,391.79 Cr | ₹1,679.36 Cr | |
| EBITDA | ₹404.74 Cr | ₹338.27 Cr | ₹402.15 Cr | ₹475.93 Cr |
| ₹219.67 Cr | ₹153.49 Cr | ₹201.64 Cr | ₹258.12 Cr | |
| Diluted EPS | ₹5.09 | ₹3.55 | ₹4.67 | ₹6.87 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,592.82 Cr | ₹1,912.10 Cr | ₹2,139.22 Cr | ₹2,813.15 Cr | |
| ₹575.68 Cr | ₹686.71 Cr | ₹682.07 Cr | ₹364.19 Cr | |
| Stockholders' equity | ₹686.56 Cr | ₹882.80 Cr | ₹1,052.09 Cr | ₹2,021.98 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹195.03 Cr | ₹361.44 Cr | ₹215.38 Cr | ₹329.09 Cr | |
| Investing cash flow | ₹-179.63 Cr | ₹-254.55 Cr | ₹-100.15 Cr | ₹-333.45 Cr |
| ₹1.51 Cr | ₹-130.30 Cr | ₹-88.86 Cr | ₹120.84 Cr | |
| Capital expenditure | ₹-98.43 Cr | ₹-71.45 Cr | ₹-145.12 Cr | ₹-119.69 Cr |
| End cash position | ₹100.05 Cr | ₹76.63 Cr | ₹103.00 Cr | ₹236.85 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 25–Jun 26(4Q) |
|---|---|
| Promoter | 82.89% |
| Public | 17.11% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Park Medi World Limited | ₹12,003.36 Cr | ₹277.9 | 42.6 | 5.94 | 12.8% | 0.18 | +18.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
12 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.